보고서 요약(국문)

시장 개요
전 세계 병원 감염 시장은 2022년 144억 달러 규모에 달했으며, 2030년까지 195억 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 전 세계 병원 감염 시장은 2023년부터 2030년까지 연평균 3.8%의 성장률을 기록할 것으로 예상됩니다. 병원 입원 환자 수 증가와 신약 임상 시험 확대가 병원 감염 시장 수요 증가를 견인하고 있습니다.
환자가 의료기관이나 병원에서 약물 치료를 받는 과정에서 병원 감염(의료 관련 감염)에 걸릴 수 있습니다. 환자의 폐, 피부, 혈액, 소화기 또는 비뇨기계가 감염될 수 있으며, 패혈증, 수술 부위 감염, 카테터 관련 요로 감염 등이 대표적인 의료 관련 감염입니다. 이러한 질환 치료에는 항바이러스제 또는 항균제가 사용됩니다.

병원 감염 시장은 항균제, 항바이러스제, 항진균제 및 기타 약물 유형을 포함하며, 이는 병원 감염 시장 점유율 증가에 기여했습니다. 전 세계 병원 감염 치료제 시장은 연구 개발 증가와 각국의 신약 승인 추진 등 여러 요인으로 인해 성장하고 있으며, 이러한 요인들은 병원 감염 시장 성장에 긍정적인 영향을 미치고 있습니다.

시장 동향
병원 감염 발생률 증가가 병원 감염 시장 성장을 견인
미국 질병통제예방센터(CDC)에 따르면, 미국 병원에서만 매년 170만 건의 감염 사례와 9만 9천 명의 사망자가 발생할 것으로 예상됩니다. 이 중 요로 감염이 전체 의료 관련 감염의 32%, 수술 부위 감염이 22%, 폐렴(폐 감염)이 15%, 혈류 감염이 14%를 차지합니다.

또한, 캐나다 공중보건국은 2022년 8월에 캐나다 주요 대학병원에 입원한 환자의 2%가 입원 기간 동안 감염에 걸릴 것이며, 입원 환자의 3%에서 10%가 언제든지 항생제 내성균에 감염되었거나 내성균을 보유하고 있을 것이라고 예측했습니다. 따라서 병원 감염의 증가 추세가 병원 감염 관련 시장의 성장을 견인하고 있습니다.
인식 제고와 연구 개발은 제조업체에게 수익성 높은 기회를 창출합니다.
의료 관련 감염으로 인한 높은 사망률과 이환율은 의료 산업에 매년 수십억 달러의 손실을 초래합니다. 수년에 걸쳐 중심 정맥관 모니터링, 설치 및 추적, 감염 환자 격리에 대한 많은 지침이 만들어졌습니다. 의미 있는 변화를 가져오는 유일한 방법은 모든 의료진이 협력하는 것입니다. 환자와 의료진 간의 감염원 확산을 예방하는 것이 병원에서 사용되는 주요 전략입니다.
감염된 환자와 가장 먼저 접촉하는 경우가 많은 간호사는 예방에 필수적입니다. 감염 예방의 핵심은 손 씻기와 모든 사람이 명시된 지침을 준수하는 것입니다. 카테터 고정, 의료진의 감염 관리 교육, 손 씻기, 침습적 시술 중 무균 기술 사용 등 수많은 1A 등급 권고사항들이 병원 감염 시장 규모 성장에 기여할 것으로 예상됩니다.
하지만 엄격한 약가 책정은 시장 성장을 저해할 수 있습니다.
약가 책정은 여러 이해관계자가 얽혀 있는 복잡한 과정이며, 비용 효율성에 큰 영향을 미칩니다. 가치 기반 가격 책정은 약품의 비용 효율적인 가격을 산정하는 기법입니다.
가치 기반 가격 책정이 신약의 비용에 어떤 영향을 미칠지는 아직 명확하지 않지만, 핵심 결정 요인은 '가치'라는 개념이 될 것입니다. 가치는 환자의 건강에 미치는 약효뿐 아니라 사회 전반에 미치는 영향, 질병의 건강상 영향까지 포함할 수 있습니다. 따라서 위에서 언급한 요인들이 병원 감염 시장 성장을 제한하는 요인으로 작용할 것입니다.

COVID-19 영향 분석
COVID-19 팬데믹과 전 세계 여러 국가의 봉쇄 조치는 모든 산업 분야 기업의 재정 건전성에 영향을 미쳤습니다. 따라서, 코로나19 공중보건 비상사태 기간 동안 미국 식품의약국(FDA)은 임상시험 참여자의 안전을 보장하고, 우수 임상시험관리기준(GCP)을 준수하며, 임상시험의 무결성에 대한 위험을 최소화하는 등, 스폰서와 연구자를 지원하기 위한 일반적인 고려 사항을 포함하는 지침을 발표했습니다.
러시아-우크라이나 전쟁 영향 분석
러시아-우크라이나 분쟁은 해당 지역의 주요 시장 참여자 수가 적기 때문에 전 세계 병원 감염 시장에 중간 정도의 영향을 미칠 것으로 예상됩니다. 그러나 원자재 수출입의 영향은 예측 기간 동안 전 세계 병원 감염 시장 성장에 거의 영향을 미치지 않을 것으로 예상됩니다.
세분화 분석
전 세계 병원 감염 시장은 감염 유형, 약물 유형, 최종 사용자 및 지역별로 세분화됩니다.
약물 유형 부문에서 항균제는 신제품 출시 증가에 힘입어 시장 점유율의 37.3%를 차지합니다.
항균제는 항생제라고도 하며, 세균 감염 치료에 사용되는 의약품의 한 종류입니다. 항생제는 단백질 합성이나 세포벽 형성 같은 특정 세균 또는 세균의 특정 과정에 작용합니다. 질병의 종류와 정도에 따라 정확한 치료법과 용량이 결정됩니다. 항균제는 정맥 주사, 국소 도포, 경구 투여 등 다양한 방법으로 투여할 수 있습니다.
최근에는 새로운 표적을 가진 많은 신약들이 출시되었지만, 일부는 아직 FDA 승인을 기다리고 있습니다. 거대고리 항생제, 최근 개발된 세팔로스포린, 글리코펩타이드, 카바페넴, 플레우로뮤틸린 등이 그 예입니다. 오늘날 세균 감염 치료에 가장 많이 사용되는 항생제 계열 중 하나는 락탐계 항생제입니다. 락탐계 항생제는 세포벽 생성에 필요한 교차결합에 관여하는 PBPs를 차단하여 세균의 성장을 억제합니다.

지리적 분석
북미는 주요 업체들의 강력한 입지와 기술 발전 증가에 힘입어 시장 점유율의 약 38.4%를 차지했습니다.
제조업체들은 북미 지역의 병원 감염 관련 기술 발전에 대한 수요 증가로 인해 사업 확장의 기회를 얻고 있습니다. 이 지역에는 많은 생산자와 공급업체가 있으며, 빠른 경제 발전으로 병원 감염 관련 제품의 산업 생산이 증가하여 수요 증가를 촉진했습니다.
북미는 다수의 생산자와 공급업체를 보유하고 있으며, 이 지역의 빠른 경제 발전으로 산업 생산이 증가하여 병원 감염 관련 제품에 대한 수요를 증가시켰습니다.
새로운 약물이나 감염 유형의 증가는 시장 성장을 견인할 것입니다. 또한 기술 발전, 규제 승인 및 신제품 출시도 성장을 촉진합니다. 연구자들은 감염성 질환에 대한 다양한 진단 접근법에 대해 더 잘 알게 되면서 이 지역 시장이 확대되고 있습니다. 이러한 요인들이 북미 시장의 지배력을 보여줍니다.

경쟁 환경
병원 감염 시장의 주요 글로벌 업체로는 F Hoffmann-la Roche Ltd, Pfizer Inc., AbbVie Inc., AstraZeneca, GSK plc, Innoviva, Eli Lilly and Company, Steris, Cipla Inc., Basilea Pharmaceutica Ltd. 등이 있습니다.
보고서 구매 이유

• 감염 유형, 약물 유형, 최종 사용자 및 지역별 글로벌 병원 감염 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 병원 감염 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품 정보를 담은 Excel 파일 형태의 제품 맵핑을 제공합니다.

글로벌 병원 감염 시장 보고서는 약 53개의 표, 54개의 그림, 그리고 195페이지 분량으로 구성될 예정입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Hospital Acquired Infections Market reached US$ 14.4 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 19.5 billion by 2030. The global hospital acquired infections market is expected to exhibit a CAGR of 3.8% during the forecast period 2023-2030. The increasing hospital admissions and the growing clinical trials for novel drugs are driving up demand for hospital acquired infections market trends.
When a patient receives medication at a healthcare center or from a doctor, they may contract hospital-acquired infections, also known as healthcare-associated infections. The patient's lungs, skin, blood, digestive or urinary tracts could all get infected. Sepsis, surgical site infections, catheter-associated urinary tract infections and others are examples of healthcare-associated infections. Drugs that are antiviral or antibacterial are used to treat these illnesses.
The hospital acquired infections market scope comprises drug type as antibacterial drugs, antiviral drugs, antifungal drugs and others, which has increased the hospital acquired infections market share. The global market for hospital acquired infections is expanding as a result of factors including increasing research and development and their upcoming medical approvals across countries are also creating a positive outlook for the hospital acquired infections market growth.
Market Dynamics
An Increase in the Incidence of Hospital Acquired Infections Drive the Growth of the Hospital Acquired Infections Market
According to the Centers for Disease Control (CDC), HAIs are expected to cause 1.7 million illnesses and 99,000 deaths annually in American hospitals alone. Of these illnesses, urinary tract infections account for 32% of all healthcare-acquired infections, surgical site infections for 22%, pneumonia (lung infections) for 15% and bloodstream infections for 14%.
Additionally, the Public Health Agency of Canada predicted in August 2022 that 2% of patients admitted to major academic hospitals in Canada will contract an infection during their stay and that 3% to 10% of hospitalized patients will at any given time be infected with or carrying an antimicrobial-resistant organism. Hence, the growing hospital acquired infection is driving the hospital acquired infections market.
Rising Awareness and Research and Development Creates Lucrative Opportunities for Manufacturers
High mortality and morbidity rates from healthcare-associated infections cost the healthcare industry billions of dollars annually. Many guidelines for monitoring, setting up and tracking central lines and isolating infected patients have been created throughout the years. The only way to make a difference is for all healthcare teams to work together. Preventing the spread of infectious agents amongst patients and medical personnel is the main tactic used in hospitals.
Since they frequently come into contact with infected patients initially, nurses are essential to prevention. The key to preventing infections is hand washing and ensuring that everyone abides by the stated guidelines. Numerous category 1A recommendations, such as securing catheters, teaching medical staff about infection control practices, hand washing and the use of aseptic techniques during invasive procedures. Thus these factors will create opportunities for the growth of hospital acquired infections market size.
Stringent Pricing of Drugs will Hamper the Growth of the Market.
Drug pricing is a difficult process that involves numerous players and greatly affects cost-effectiveness. Pricing based on value is a technique for figuring out the cost-effective price for the medicine.
Although it is not yet clear how value-based pricing will affect the costs of new antibacterial drugs, a key determining factor will be the notion of value, which may include not only the effect of the drug on the patient's health but also its wider impact on society and the health effects of the disease. Hence these above-mentioned factors are limiting the hospital-acquired infections market’s growth.
COVID-19 Impact Analysis
The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP) and minimizing risks to trial integrity.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict is estimated to have a moderate impact on the global hospital-acquired infections market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global hospital acquired infections market growth over the forecast period.
Segment Analysis
The global hospital acquired infections market is segmented based on infection type, drug type, end user and region.
Antibacterial drugs from the Drug Type Segment Account for 37.3% of the Market Share Owing to Rising Novel Product Launches
Antibacterial medications, also referred to as antibiotics, are a class of pharmaceuticals used to treat bacterial infections. Antibiotics focus on specific bacteria or bacterial processes, like protein synthesis or cell wall construction. The nature and extent of the ailment will determine the exact treatment and dosage. Antibacterial medications can be administered intravenously, topically, or orally, among other ways.
Recently, many new antimicrobial drugs with new targets have hit the market, albeit others are still awaiting FDA approval. Macrocyclic antibiotics, more recent cephalosporins, glycopeptides, carbapenems, pleuromutilin and other ones are a few of them. Today, one of the antibiotic classes most frequently recommended for the treatment of bacterial infections is lactams. By blocking PBPs, which are necessary for cross-linking in cell wall production, they prevent bacterial growth.
Geographical Analysis
North America Accounted for Approximately 38.4% of the Market Share Owing to the Strong Presence of Major Players and Increasing Technological Advancements
Manufacturers have chances to expand their operations in this region because of the rising demand for hospital-acquired infections for advancements in North America. The area has many producers and suppliers and its rapid economic development has raised industrial production of hospital-acquired infections, which has increased the demand.
North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand for hospital acquired infections.
Rising new drug or infection types will drive market growth. Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of diagnostic approaches for infectious disorders, leading to the expansion of the market in this region. These factors show the dominance of North America.
Competitive Landscape
The major global players in the hospital acquired infections market include F Hoffmann-la Roche Ltd, Pfizer Inc., AbbVie Inc., AstraZeneca, GSK plc, Innoviva, Eli Lilly and Company, Steris, Cipla Inc. and Basilea Pharmaceutica Ltd. among others.
Why Purchase the Report?
• To visualize the global hospital-acquired infections market segmentation based on infection type, drug type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hospital-acquired infections market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Hospital Acquired Infections Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.
Target Audience 2023
• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Infection Type
3.2. Snippet by Drug Type
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Rising Clinical Trials by Key Companies
4.1.1.2. Rising Incidence of Hospital-Acquired Infection
4.1.2. Restraints
4.1.2.1. Stringent Pricing of Drugs
4.1.3. Opportunity
4.1.3.1. Rising Awareness and Research and Development
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. By Infection Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
7.1.2. Market Attractiveness Index, By Infection Type
7.2. Gastrointestinal Infections *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Urinary Tract Infections
7.4. Ventilator-Associated Pneumonia
7.5. Bloodstream Infections
7.6. Surgical Site Infections
7.7. Others
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Antibacterial Drug *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Vancomycin
8.2.4. Beta-Lactams
8.2.5. Quinolones
8.2.6. Others
8.3. Antiviral Drug
8.3.1. Acyclovir
8.3.2. Foscarnet
8.4. Antifungal Drug
8.4.1. Amphotericin B
8.4.2. Triazoles
8.5. Others
8.5.1. Antiparasitic
8.5.2. Antiprotozoal
8.5.3. Anti-TB Treatment
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals & ICUs *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical & Diagnostic Centers
9.4. Nursing Homes & Maternity Centers
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The U.K.
10.3.6.3. France
10.3.6.4. Spain
10.3.6.5. Italy
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
Australia
10.5.6.4. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Merck & Co., Inc. *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Pfizer Inc.
12.3. AbbVie Inc.
12.4. AstraZeneca
12.5. GSK plc
12.6. Innoviva
12.7. ELI LILLY AND COMPANY
12.8. STERIS
12.9. Cipla Inc.
12.10. Basilea Pharmaceutica Ltd.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Merck & Co., Inc., 4.	Key Developments, Pfizer Inc., AbbVie Inc., AstraZeneca, GSK plc, Innoviva, ELI LILLY AND COMPANY, STERIS, Cipla Inc., Basilea Pharmaceutica Ltd.

표 목록 (Tables)

List of Tables

Table 1 Global Hospital Acquired Infections Market Value, By Infection Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Hospital Acquired Infections Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Hospital Acquired Infections Market Value, By End User, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Hospital Acquired Infections Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Hospital Acquired Infections Market Value, By Infection Type, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Hospital Acquired Infections Market Value, By Infection Type, 2021-2030 (US$ Billion)

Table 7 Global Hospital Acquired Infections Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Billion)

Table 8 Global Hospital Acquired Infections Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 9 Global Hospital Acquired Infections Market Value, By End User, 2022, 2026 & 2030 (US$ Billion)

Table 10 Global Hospital Acquired Infections Market Value, By End User, 2021-2030 (US$ Billion)

Table 11 Global Hospital Acquired Infections Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 12 Global Hospital Acquired Infections Market Value, By Region, 2021-2030 (US$ Billion)

Table 13 North America Hospital Acquired Infections Market Value, By Infection Type, 2021-2030 (US$ Billion)

Table 14 North America Hospital Acquired Infections Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 15 North America Hospital Acquired Infections Market Value, By End User, 2021-2030 (US$ Billion)

Table 16 North America Hospital Acquired Infections Market Value, By Country, 2021-2030 (US$ Billion)

Table 17 South America Hospital Acquired Infections Market Value, By Infection Type, 2021-2030 (US$ Billion)

Table 18 South America Hospital Acquired Infections Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 19 South America Hospital Acquired Infections Market Value, By End User, 2021-2030 (US$ Billion)

Table 20 South America Hospital Acquired Infections Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 Europe Hospital Acquired Infections Market Value, By Infection Type, 2021-2030 (US$ Billion)

Table 22 Europe Hospital Acquired Infections Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 23 Europe Hospital Acquired Infections Market Value, By End User, 2021-2030 (US$ Billion)

Table 24 Europe Hospital Acquired Infections Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 Asia-Pacific Hospital Acquired Infections Market Value, By Infection Type, 2021-2030 (US$ Billion)

Table 26 Asia-Pacific Hospital Acquired Infections Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 27 Asia-Pacific Hospital Acquired Infections Market Value, By End User, 2021-2030 (US$ Billion)

Table 28 Asia-Pacific Hospital Acquired Infections Market Value, By Country, 2021-2030 (US$ Billion)

Table 29 Middle East & Africa Hospital Acquired Infections Market Value, By Infection Type, 2021-2030 (US$ Billion)

Table 30 Middle East & Africa Hospital Acquired Infections Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 31 Middle East & Africa Hospital Acquired Infections Market Value, By End User, 2021-2030 (US$ Billion)

Table 32 Merck & Co., Inc. : Overview

Table 33 Merck & Co., Inc. : Product Portfolio

Table 34 Merck & Co., Inc. : Key Developments

Table 35 Pfizer Inc.: Overview

Table 36 Pfizer Inc.: Product Portfolio

Table 37 Pfizer Inc.: Key Developments

Table 38 AbbVie Inc.: Overview

Table 39 AbbVie Inc.: Product Portfolio

Table 40 AbbVie Inc.: Key Developments

Table 41 AstraZeneca : Overview

Table 42 AstraZeneca : Product Portfolio

Table 43 AstraZeneca : Key Developments

Table 44 GSK plc: Overview

Table 45 GSK plc: Product Portfolio

Table 46 GSK plc: Key Developments

Table 47 Innoviva: Overview

Table 48 Innoviva: Product Portfolio

Table 49 Innoviva: Key Developments

Table 50 ELI LILLY AND COMPANY: Overview

Table 51 ELI LILLY AND COMPANY: Product Portfolio

Table 52 ELI LILLY AND COMPANY: Key Developments

Table 53 STERIS : Overview

Table 54 STERIS : Product Portfolio

Table 55 STERIS : Key Developments

Table 56 Cipla Inc.: Overview

Table 57 Cipla Inc.: Product Portfolio

Table 58 Cipla Inc.: Key Developments

Table 59 Basilea Pharmaceutica Ltd.: Overview

Table 60 Basilea Pharmaceutica Ltd.: Product Portfolio

Table 61 Basilea Pharmaceutica Ltd.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Hospital Acquired Infections Market Share, By Infection Type, 2022 & 2030 (%)

Figure 3 Global Hospital Acquired Infections Market Share, By Drug Type, 2022 & 2030 (%)

Figure 4 Global Hospital Acquired Infections Market Share, By End User, 2022 & 2030 (%)

Figure 5 Global Hospital Acquired Infections Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Hospital Acquired Infections Market Y-o-Y Growth, By Infection Type, 2022-2030 (%)

Figure 7 Gastrointestinal Infections Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 8 Urinary Tract Infections Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 9 Ventilator-Associated Pneumonia Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 10 Bloodstream Infections Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 11 Surgical Site Infections Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 12 Others Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 13 Global Hospital Acquired Infections Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 14 Antibacterial Drug Drug Type in Global Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 15 Antiviral Drug Drug Type in Global Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 16 Antifungal Drug Drug Type in Global Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 17 Others Drug Type in Global Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 18 Global Hospital Acquired Infections Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 19 Hospitals & ICUs End User in Global Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 20 Ambulatory Surgical & Diagnostic Centers End User in Global Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 21 Nursing Homes & Maternity Centers End User in Global Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 22 Others End User in Global Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 23 Global Hospital Acquired Infections Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 24 North America Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 25 Asia-Pacific Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 26 Europe Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 27 South America Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 28 Middle East and Africa Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 29 North America Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 30 North America Hospital Acquired Infections Market Share, By Infection Type, 2022 & 2030 (%)

Figure 31 North America Hospital Acquired Infections Market Share, By Drug Type, 2022 & 2030 (%)

Figure 32 North America Hospital Acquired Infections Market Share, By End User, 2022 & 2030 (%)

Figure 33 North America Hospital Acquired Infections Market Share, By Country, 2022 & 2030 (%)

Figure 34 South America Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 35 South America Hospital Acquired Infections Market Share, By Infection Type, 2022 & 2030 (%)

Figure 36 South America Hospital Acquired Infections Market Share, By Drug Type, 2022 & 2030 (%)

Figure 37 South America Hospital Acquired Infections Market Share, By End User, 2022 & 2030 (%)

Figure 38 South America Hospital Acquired Infections Market Share, By Country, 2022 & 2030 (%)

Figure 39 Europe Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 40 Europe Hospital Acquired Infections Market Share, By Infection Type, 2022 & 2030 (%)

Figure 41 Europe Hospital Acquired Infections Market Share, By Drug Type, 2022 & 2030 (%)

Figure 42 Europe Hospital Acquired Infections Market Share, By End User, 2022 & 2030 (%)

Figure 43 Europe Hospital Acquired Infections Market Share, By Country, 2022 & 2030 (%)

Figure 44 Asia-Pacific Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 45 Asia-Pacific Hospital Acquired Infections Market Share, By Infection Type, 2022 & 2030 (%)

Figure 46 Asia-Pacific Hospital Acquired Infections Market Share, By Drug Type, 2022 & 2030 (%)

Figure 47 Asia-Pacific Hospital Acquired Infections Market Share, By End User, 2022 & 2030 (%)

Figure 48 Asia-Pacific Hospital Acquired Infections Market Share, By Country, 2022 & 2030 (%)

Figure 49 Middle East & Africa Hospital Acquired Infections Market Value, 2021-2030 (US$ Billion)

Figure 50 Middle East & Africa Hospital Acquired Infections Market Share, By Infection Type, 2022 & 2030 (%)

Figure 51 Middle East & Africa Hospital Acquired Infections Market Share, By Drug Type, 2022 & 2030 (%)

Figure 52 Middle East & Africa Hospital Acquired Infections Market Share, By End User, 2022 & 2030 (%)

Figure 53 Merck & Co., Inc. : Financials

Figure 54 Pfizer Inc.: Financials

Figure 55 AbbVie Inc.: Financials

Figure 56 AstraZeneca : Financials

Figure 57 GSK plc: Financials

Figure 58 Innoviva: Financials

Figure 59 ELI LILLY AND COMPANY: Financials

Figure 60 STERIS : Financials

Figure 61 Cipla Inc.: Financials

Figure 62 Basilea Pharmaceutica Ltd.: Financials

글로벌 병원 감염 시장 – 2023-2030

Global Hospital Acquired Infections Market - 2023-2030